BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 14661444)

  • 21. Establishment of reference intervals of monomeric prolactin to identify macroprolactinemia in Chinese patients with increased total prolactin.
    Hu Y; Ni J; Zhang B; Cheng W; Zhang H; Ye H; Ji L; Lu B; Guan M
    BMC Endocr Disord; 2021 Oct; 21(1):197. PubMed ID: 34620143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Macroprolactinemia in patients with hyperprolactinemia: an experience from a single tertiary center.
    Chutpiboonwat P; Yenpinyosuk K; Sridama V; Kunjan S; Klaimukh K; Snabboon T
    Pan Afr Med J; 2020; 36():8. PubMed ID: 32550971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia.
    Espinós JJ; Vanrell C; Gich I; Urgell E; Calaf J
    Gynecol Endocrinol; 2017 Feb; 33(2):148-151. PubMed ID: 27841032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macroprolactinemia: diagnostic, clinical, and pathogenic significance.
    Shimatsu A; Hattori N
    Clin Dev Immunol; 2012; 2012():167132. PubMed ID: 23304187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia.
    Overgaard M; Pedersen SM
    Clin Chem Lab Med; 2017 Oct; 55(11):1744-1753. PubMed ID: 28236625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Macroprolactinemia--a more common cause of hyperprolactinemia than generally believed].
    Sane T; Hekim C; Alfthan H; Stenman UH; Välimäki M
    Duodecim; 2002; 118(16):1671-5. PubMed ID: 12271945
    [No Abstract]   [Full Text] [Related]  

  • 27. [Screening and detection of patients with macroprolactinemia by application of polyethylene glycol precipitation method].
    Chen YJ; Zhou YL; Xu L; Yan J
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Mar; 43(2):187-92. PubMed ID: 24782376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact on clinical practice of routine screening for macroprolactin.
    Gibney J; Smith TP; McKenna TJ
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3927-32. PubMed ID: 15811931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Macroprolactinemia in People Detected to Have Hyperprolactinemia.
    Sharma LK; Dutta D; Sharma N; Kulshreshtha B; Lal S; Sethi R
    J Lab Physicians; 2021 Dec; 13(4):353-357. PubMed ID: 34975255
    [No Abstract]   [Full Text] [Related]  

  • 30. Should macroprolactin be measured in all hyperprolactinaemic sera?
    McKenna TJ
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):466-9. PubMed ID: 19320649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with macroprolactinaemia: clinical and radiological features.
    Donadio F; Barbieri A; Angioni R; Mantovani G; Beck-Peccoz P; Spada A; Lania AG
    Eur J Clin Invest; 2007 Jul; 37(7):552-7. PubMed ID: 17576206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolactin Level in Polycystic Ovary Syndrome (PCOS): An approach to the diagnosis and management.
    Davoudi Z; Araghi F; Vahedi M; Mokhtari N; Gheisari M
    Acta Biomed; 2021 Nov; 92(5):e2021291. PubMed ID: 34738596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Misleading diagnosis of hyperprolactinemia in women].
    Paepegaey AC; Veron L; Wimmer MC; Christin-Maitre S
    Gynecol Obstet Fertil; 2016 Mar; 44(3):181-6. PubMed ID: 26966035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Macroprolactinemia associated with pituitary macroadenoma: treatment with quinagolide].
    Lakatos G; Szücs N; Kender Z; Czirják S; Rácz K
    Orv Hetil; 2010 Jun; 151(26):1072-5. PubMed ID: 20558354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.
    Tamer G; Telci A; Mert M; Uzum AK; Aral F; Tanakol R; Yarman S; Boztepe H; Colak N; Alagöl F
    Endocrine; 2012 Feb; 41(1):138-43. PubMed ID: 21959531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Macroprolactinemia: predictability on clinical basis and detection by PEG precipitation with two different immunometric methods.
    Amadori P; Dilberis C; Marcolla A; Pinamonti M; Menapace P; Dal Bosco F
    J Endocrinol Invest; 2003 Feb; 26(2):148-56. PubMed ID: 12739743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays.
    Smith TP; Suliman AM; Fahie-Wilson MN; McKenna TJ
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5410-5. PubMed ID: 12466327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect.
    Dagdelen S; Usman A
    Minerva Endocrinol; 2010 Jun; 35(2):53-9. PubMed ID: 20595935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Neutral Effect of Metformin Treatment on Macroprolactin Content in Women with Macroprolactinemia.
    Krysiak R; Szkróbka W; Okopień B
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):223-228. PubMed ID: 27750350
    [No Abstract]   [Full Text] [Related]  

  • 40. What is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
    Kim SI; Yoon JH; Park DC; Yang SH; Kim YI
    Int J Med Sci; 2023; 20(4):463-467. PubMed ID: 37057215
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.